Edition:
United States

Profile: Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

61.41EUR
17 Nov 2017
Change (% chg)

€-1.29 (-2.06%)
Prev Close
€62.70
Open
€62.69
Day's High
€62.80
Day's Low
€61.19
Volume
261,443
Avg. Vol
314,460
52-wk High
€79.05
52-wk Low
€54.84

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Company Address

Ucb SA

Allee de la Recherche, 60
ANDERLECHT     1070
P: +322.5599999
F: +322.5599900

Company Web Links